Literature DB >> 25244076

Silk-elastin-like protein polymer matrix for intraoperative delivery of an oncolytic vaccinia virus.

Daniel L Price1,2, Pingdong Li1,3, Chun-Hao Chen1, Danni Wong1,3, Zhenkun Yu3, Nanhai G Chen4,5, Yong A Yu4,5, Aladar A Szalay4,5,6, Joseph Cappello4,7, Yuman Fong8, Richard J Wong1.   

Abstract

BACKGROUND: Oncolytic viral efficacy may be limited by the penetration of the virus into tumors. This may be enhanced by intraoperative application of virus immediately after surgical resection.
METHODS: Oncolytic vaccinia virus GLV-1h68 was delivered in silk-elastin-like protein polymer (SELP) in vitro and in vivo in anaplastic thyroid carcinoma cell line 8505c in nude mice.
RESULTS: GLV-1h68 in SELP infected and lysed anaplastic thyroid cancer cells in vitro equally as effectively as in phosphate-buffered saline (PBS), and at 1 week retains a thousand fold greater infectious plaque-forming units. In surgical resection models of residual tumor, GLV-1h68 in SELP improves tumor control and shows increased viral β-galactosidase expression as compared to PBS.
CONCLUSION: The use of SELP matrix for intraoperative oncolytic viral delivery protects infectious viral particles from degradation, facilitates sustained viral delivery and transgene expression, and improves tumor control. Such optimization of methods of oncolytic viral delivery may enhance therapeutic outcomes.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  anaplastic thyroid carcinoma; oncolytic virus; surgery; vaccinia; viral therapy

Mesh:

Substances:

Year:  2015        PMID: 25244076      PMCID: PMC4975925          DOI: 10.1002/hed.23877

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  21 in total

1.  In-situ self-assembling protein polymer gel systems for administration, delivery, and release of drugs.

Authors:  J Cappello; J W Crissman; M Crissman; F A Ferrari; G Textor; O Wallis; J R Whitledge; X Zhou; D Burman; L Aukerman; E R Stedronsky
Journal:  J Control Release       Date:  1998-04-30       Impact factor: 9.776

2.  Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.

Authors:  J Nemunaitis; F Khuri; I Ganly; J Arseneau; M Posner; E Vokes; J Kuhn; T McCarty; S Landers; A Blackburn; L Romel; B Randlev; S Kaye; D Kirn
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

3.  Experience of anti-vaccinia immunoglobulin in the United Kingdom.

Authors:  J C Sharp; W B Fletcher
Journal:  Lancet       Date:  1973-03-24       Impact factor: 79.321

4.  Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus.

Authors:  Wilson Mok; Yves Boucher; Rakesh K Jain
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

5.  Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus.

Authors:  Shu-Fu Lin; Zhenkun Yu; Christopher Riedl; Yanghee Woo; Qian Zhang; Yong A Yu; Tatyana Timiryasova; Nanhai Chen; Jatin P Shah; Aladar A Szalay; Yuman Fong; Richard J Wong
Journal:  Surgery       Date:  2007-11-05       Impact factor: 3.982

6.  Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins.

Authors:  Yong A Yu; Shahrokh Shabahang; Tatyana M Timiryasova; Qian Zhang; Richard Beltz; Ivaylo Gentschev; Werner Goebel; Aladar A Szalay
Journal:  Nat Biotechnol       Date:  2004-02-08       Impact factor: 54.908

7.  Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.

Authors:  Qian Zhang; Yong A Yu; Ena Wang; Nanhai Chen; Robert L Danner; Peter J Munson; Francesco M Marincola; Aladar A Szalay
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

8.  Influence of polymer structure and biodegradation on DNA release from silk-elastinlike protein polymer hydrogels.

Authors:  David Hwang; Vikas Moolchandani; Ramesh Dandu; Mohamed Haider; Joseph Cappello; Hamidreza Ghandehari
Journal:  Int J Pharm       Date:  2008-11-05       Impact factor: 5.875

9.  Local sustained delivery of oncolytic adenovirus with injectable alginate gel for cancer virotherapy.

Authors:  J-W Choi; E Kang; O-J Kwon; T J Yun; H-K Park; P-H Kim; S W Kim; J H Kim; C-O Yun
Journal:  Gene Ther       Date:  2013-03-21       Impact factor: 5.250

10.  Oncolytic vaccinia therapy of squamous cell carcinoma.

Authors:  Zhenkun Yu; Sen Li; Peter Brader; Nanhai Chen; Yong A Yu; Qian Zhang; Aladar A Szalay; Yuman Fong; Richard J Wong
Journal:  Mol Cancer       Date:  2009-07-06       Impact factor: 27.401

View more
  3 in total

1.  Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.

Authors:  Ke Jiang; Cuiping Song; Lingkai Kong; Lulu Hu; Guibin Lin; Tian Ye; Gang Yao; Yupeng Wang; Haibo Chen; Wei Cheng; Martin P Barr; Quentin Liu; Guirong Zhang; Chan Ding; Songshu Meng
Journal:  BMC Cancer       Date:  2018-07-18       Impact factor: 4.430

Review 2.  Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements.

Authors:  Ke-Tao Jin; Wen-Lin Du; Yu-Yao Liu; Huan-Rong Lan; Jing-Xing Si; Xiao-Zhou Mou
Journal:  Cancers (Basel)       Date:  2021-02-03       Impact factor: 6.639

Review 3.  Oncolytic virotherapy for head and neck cancer: current research and future developments.

Authors:  Akshiv Malhotra; Arun Sendilnathan; Matthew O Old; Trisha M Wise-Draper
Journal:  Oncolytic Virother       Date:  2015-07-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.